首頁 > 市場調查報告書 > 製藥

麻醉

市場調查報告書

商品編碼

1733329

全球麻醉劑市場規模（按應用、給藥途徑、給藥方式、區域範圍和預測）

Global Anesthesia Drugs Market Size By Application, By Administrative Route, By Mode Of Delivery, By Geographic Scope And Forecast

出版日期: 2025年05月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

麻醉劑市場規模及預測

麻醉劑市場規模預計在 2024 年達到 67.7 億美元，到 2032 年將達到 87.7 億美元，2026 年至 2032 年的複合年成長率為 3.64%。

麻醉劑，俗稱麻醉劑，是用來引起暫時失去感覺和意識的藥物，使醫療程序更容易進行，且不會產生疼痛或痛苦。

麻醉劑是一種能夠產生可控的無意識狀態或局部麻木狀態的藥物，使患者能夠接受手術或醫療程序而不會感到疼痛或不適。麻醉劑主要分為兩大類：全身麻醉劑和局部麻醉劑。

這些藥物的主要目的是阻斷手術介入期間的感覺，尤其是疼痛。麻醉劑使患者感到舒適並且不知道正在進行的手術，這對於小手術和大手術都至關重要。

麻醉劑透過與中樞神經系統 (CNS) 相互作用並抑制疼痛訊號從周圍神經向大腦傳輸而發揮作用。全身麻醉劑會改變神經傳導物質活性，局部麻醉劑會阻斷神經纖維中的鈉通道。

麻醉劑市場動態

影響麻醉劑市場的關鍵市場動態是：

關鍵市場促進因素

外科手術數量增加：根據美國麻醉師協會的數據，全球每年進行超過 3.1 億次外科手術，僅在美國就進行約 4,000 萬至 5,000 萬次外科手術。對外科手術的高需求需要有效的麻醉解決方案，從而推動市場成長。

慢性病盛行率上升：癌症、心血管疾病和骨關節炎等慢性病盛行率上升是麻醉劑需求的主要促進因素。根據世界衛生組織 (WHO) 的數據，心血管疾病是全球第一大死因，並推動了對需要全身麻醉的外科手術的需求。這一趨勢凸顯了麻醉在複雜醫療狀況管理中的重要性。

技術進步：麻醉劑配方和輸送方法的不斷創新正在提高患者的安全性和有效性。最近的趨勢包括開發超短效麻醉劑和改善患者預後的先進監測系統。在這些技術進步的推動下，美國全身麻醉劑市場預計在 2024 年至 2030 年期間的複合年成長率為 2.8%。

政府資金和支持：增加私人和政府機構對製藥製造研究和開發的資金也很重要。例如，美國政府旨在改善醫療保健基礎設施的舉措正在間接推動對麻醉劑的需求。

主要市場挑戰

麻醉劑高成本：麻醉劑價格過高會限制人們獲得所需藥物的機會，尤其是在低收入地區。根據報告，預計在預測期內，高昂的手術成本和品牌藥物成本將抑制市場成長。這種經濟障礙常常阻礙人們尋求必要的醫療干預，特別是在醫療預算有限的低度開發國家。

缺乏醫療保健基礎設施：世界衛生組織 (WHO) 強調，醫療保健基礎設施不足直接影響手術的可用性和可近性，進而限制對麻醉劑的需求。這種差距在新興國家尤其明顯，因為這些國家的麻醉師與認證麻醉護理師的比例較低。

意外的術中知曉：儘管處於全身麻醉狀態，患者在手術過程中仍可能意識到周圍環境。研究表明，每 1,000 名患者中大約有 1 到 2 名可能會出現這種狀況，這會導致類似於創傷後壓力症候群 (PTSD) 的長期心理問題。這種風險可能會使患者不願意接受需要全身麻醉的手術。

監管挑戰：麻醉劑市場受到美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等衛生當局的嚴格監管和核准程序。這些監管障礙可能會減緩新藥和創新產品的市場推廣，並限制醫療保健提供者和患者的選擇。

主要市場趨勢

外科手術數量的增加：全球外科手術數量正在增加，這是麻醉劑需求的主要驅動力。根據美國整形整形外科協會的數據，2022 年共進行了約 2,620 萬例外科手術。這一趨勢表明，隨著醫療保健提供者尋求滿足人口老化和日益成長的醫療需求，對有效麻醉解決方案的需求日益成長。

技術進步：得益於超短效麻醉劑和監測技術改進等進步，全身麻醉劑市場預計在 2026 年至 2032 年期間的複合年成長率為 3.5%。這些創新有望縮短恢復時間並減少術後併發症。

門診手術中心 (ASC) 的成長：門診手術中心 (ASC) 的門診手術明顯增多，這需要高效的麻醉管理。預計美國全身麻醉劑市場在 2024 年至 2030 年期間的複合年成長率將達到 2.8%，部分原因是在 ASC 中進行的手術數量不斷增加，因為這對患者來說更具成本效益且更加方便。

更重視病人安全和照護品質：在外科手術環境中，人們更加重視改善病人的治療效果和安全性，這推動了先進麻醉技術和藥物的採用。政府為提高醫療品質所做的努力也促進了這一趨勢，例如醫療保險等項目涵蓋了各種需要麻醉的外科手術。

麻醉劑市場區域分析

亞太地區

亞太地區正在對醫療保健基礎設施進行大量投資，包括新醫院和外科中心的建設。據報道，在政府改善醫療服務取得途徑和品質的措施的推動下，亞洲的醫療保健支出預計到 2025 年將達到 1 兆美元。隨著更多外科手術成為可能，這種擴張直接增加了對麻醉劑的需求。

亞太地區處於醫療創新的前沿，尤其是在麻醉技術方面。根據各種行業分析，預計該地區從 2024 年到 2033 年將以 5.09% 的速度成長，成為預測期內成長最快的麻醉劑市場。

亞太地區心血管疾病和癌症等慢性疾病的發生率正在上升，需要進行更多的外科手術。《2022年中國心血管疾病報告》顯示，心血管疾病是中國首要的死亡原因，推動了必要手術的需求。這一趨勢凸顯了在應對這些健康挑戰時對有效麻醉劑的迫切需求。

北美洲

預計北美將成為最大的地區，到 2023 年將佔全球麻醉劑市場的約 45.2%。這項優勢源自於成熟的醫療基礎設施，支持各種需要麻醉的外科手術。

據美國醫院協會稱，該地區的手術量很大，醫院每年進行大量的外科手術。 2022 年，美國將進行約 2,620 萬例外科手術，這表明對這些手術所需的麻醉劑的需求強勁。

心血管疾病和癌症等慢性疾病的發生率不斷上升，推動了對外科手術介入的需求。美國癌症協會估計，2024年將有近201萬例新的癌症病例，這將導致更多的手術，從而增加對麻醉的需求。

藥物配方和給藥方法的不斷創新正在提高患者的安全性和療效。由於技術進步縮短了恢復時間並減少了麻醉相關併發症，預計 2024 年至 2033 年間全身麻醉劑市場將以 3% 的複合年成長率成長。

麻醉劑市場區隔分析

麻醉劑市場（按應用）

一般外科
整形外科
眼科
牙科
疼痛治療

根據應用，它分為普通外科、整形外科、眼科、牙科和疼痛管理。根據記錄，2023 年普通外科手術領域佔了 46.8% 的顯著收益佔有率。這種主導地位歸因於麻醉劑在各種外科手術中的廣泛使用，使其成為市場上最大的應用領域。

麻醉劑市場（依給藥途徑）

吸入
靜脈注射
局部麻醉
局部入侵

根據給藥途徑，市場分為吸入、靜脈（IV）、局部和局部浸潤。靜脈注射藥物領域在 2023 年獲得了 56.4% 的顯著市場收益佔有率。這項優點歸功於靜脈注射的效率和可靠性，可以在手術過程中提供精確的劑量並快速開始麻醉。

麻醉劑市場（依分娩方式分類）

預填充式注射器和管瓶
安瓿
定量吸入器（MDI）

根據交付方式，市場分為預填充式注射器和管瓶、安瓿瓶和定量吸入器 (MDI)。預填充式注射器和管瓶因其便利性和效率而佔據麻醉劑市場的很大佔有率。這些在緊急情況下特別有用，因為它們可以實現準確的劑量並減少準備時間。

主要參與企業

麻醉劑市場研究報告提供了針對全球市場的寶貴見解。雅培實驗室、艾伯維公司、阿斯特捷利康公司、羅氏公司、輝瑞公司、Aspen Pharmacare Holdings Limited、百特國際公司、勃林格殷格翰國際有限公司、Claris Lifesciences Limited、丸石製藥株式會社、邁蘭製藥有限公司、邁蘭製藥有限公司、Pacira Pharmaceuticals, Inc.

我們的市場分析還設有專門針對這些主要企業的部分，我們的分析師在其中提供所有主要企業的財務報表見解以及產品基準評效和 SWOT 分析。競爭格局部分還包括上述全球參與企業的關鍵發展策略、市場佔有率和市場排名分析。

麻醉劑市場的最新趨勢
2024 年 2 月，Hikma Pharmaceuticals 推出了檸檬酸Fentanyl注射 USP，用於維持、誘導、術前用藥、麻醉和術後恢復期間的短期鎮痛。該產品滿足了各種手術環境中有效疼痛管理的迫切需求。
2023年6月，阿斯特捷利康與Aspen Global Incorporated（AGI）建立策略夥伴關係，以擴大其麻醉劑組合在美國以外的商業化。該協議涵蓋幾種成熟的麻醉劑產品，增加了它們在全球市場的供應，並利用了 AGI 廣泛的商業網路。

Increasing Surgical Procedures: The rising volume of surgical procedures globally is a primary driver of the anesthesia drugs According to the American Society of Anesthesiologists, over 310 million surgeries are performed each year worldwide, with approximately 40 to 50 million occurring in the United States alone. This high demand for surgical interventions necessitates effective anesthesia solutions, thereby propelling market growth.

Rising Prevalence of Chronic Diseases: The growing incidence of chronic diseases such as cancer, cardiovascular diseases, and osteoarthritis significantly drives the demand for anesthesia drugs. The World Health Organization reported that cardiovascular diseases are the leading cause of global mortality, increasing the need for surgical procedures that require general anesthesia. This trend underscores the importance of anesthesia in managing complex medical conditions.

Technological Advancements: Continuous innovations in anesthesia drug formulations and delivery methods enhance patient safety and efficacy. Recent advancements include the development of ultra-short-acting anesthetics and advanced monitoring systems that improve patient The U.S. general Anesthesia Drugs Market is projected to grow at a CAGR of 2.8% from 2024 to 2030, driven by these technological improvements.

Government Funding and Support: Increased funding from both private and government organizations for research and development in pharmaceutical manufacturing is another significant This funding supports the development of new and safer anesthetic agents, contributing to market expansion. For instance, U.S. government initiatives aimed at improving healthcare infrastructure indirectly boost the demand for anesthesia drugs.

Key Market Challenges:

High Cost of Anesthesia Drugs: The exorbitant prices of anesthesia drugs can limit access to necessary medications, particularly in low-income regions. According to a report, the high cost of procedures and branded drugs is expected to suppress market growth during the forecast This financial barrier often deters individuals from seeking essential medical interventions, particularly in underdeveloped countries where healthcare budgets are constrained.

Lack of Healthcare Infrastructure: In many low-income and remote areas, there is a significant lack of healthcare facilities equipped to provide anesthesia The World Health Organization has highlighted that inadequate healthcare infrastructure directly affects the availability and accessibility of surgical services, which in turn limits the demand for anesthesia drugs. This gap is particularly pronounced in developing countries where the ratio of anesthesiologists and certified anesthesia nurses is low.

Unintentional Intraoperative Awareness: A critical challenge in the anesthesia market is the phenomenon of unintentional intraoperative awareness, where patients may become aware of their surroundings during surgery despite being under general anesthesia. Studies suggest that approximately 1 to 2 out of every 1,000 patients may experience this condition, which can lead to long-term psychological issues similar to post-traumatic stress disorder (PTSD). This risk can deter patients from undergoing surgeries requiring general anesthesia.

Regulatory Challenges: The Anesthesia Drugs Market is subject to stringent regulations and approval processes imposed by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory hurdles can slow down the introduction of new drugs and innovations in the market, limiting options for healthcare providers and patients.

Key Market Trends:

Increasing Surgical Procedures: The number of surgical procedures is on the rise globally, significantly driving the demand for anesthesia drugs. According to the American Society of Aesthetic Plastic Surgeons, there were approximately 26.2 million surgical procedures performed in the U.S. in 2022. This trend indicates a growing need for effective anesthesia solutions as healthcare providers aim to meet the demands of an aging population and increasing healthcare needs.

Technological Advancements: Continuous innovations in anesthesia drug formulations and delivery methods are enhancing patient safety and The market for general anesthesia drugs is projected to grow at a CAGR of 3.5% from 2026 to 2032, driven by advancements such as ultra-short-acting anesthetics and improved monitoring technologies. These innovations are expected to improve recovery times and reduce postoperative complications.

Growth in Ambulatory Surgery Centers (ASCs): There is a notable shift towards outpatient surgeries performed in Ambulatory Surgery Centers (ASCs), which require efficient anesthesia management. The U.S. general Anesthesia Drugs Market is expected to grow at a CAGR of 2.8% from 2024 to 2030, partly due to the increasing number of procedures being performed in ASCs, which are often more cost-effective and convenient for patients.

Rising Focus on Patient Safety and Quality of Care: There is an increasing emphasis on improving patient outcomes and safety in surgical settings, which drives the adoption of advanced anesthesia techniques and drugs. Government initiatives aimed at enhancing healthcare quality also contribute to this trend, as seen in programs like Medicare that cover a wide range of surgical procedures requiring anesthesia.

Anesthesia Drugs Market Regional Analysis

Asia Pacific:

The Asia Pacific region is witnessing substantial investments in healthcare infrastructure, including the construction of new hospitals and surgical centers. According to a report, healthcare spending in Asia is projected to reach USD 1 Trillion by 2025, driven by government initiatives aimed at improving healthcare access and quality. This expansion directly increases the demand for anesthesia drugs as more surgical procedures become available.

Asia Pacific is at the forefront of medical innovation, particularly in anesthesia technology. Advances in drug formulations and monitoring devices enhance patient safety and anesthetic The region is expected to host the fastest-growing Anesthesia Drugs Market during the projected period, with a growth rate forecasted at 5.09% from 2024 to 2033, as reported by various industry analyses.

The prevalence of chronic diseases such as cardiovascular conditions and cancer is increasing in Asia Pacific, necessitating more surgical interventions. The China Cardiovascular Disease Report 2022 indicates that cardiovascular diseases are the leading cause of death in China, driving demand for surgeries that require This trend underscores the critical need for effective anesthesia drugs in managing these health challenges.

North America:

North America captured approximately 45.2% of the global Anesthesia Drugs Market in 2023, making it the largest regional This dominance is attributed to a well- established healthcare infrastructure that supports extensive surgical procedures requiring anesthesia.

The region experiences a high volume of surgeries, with the American Hospital Association reporting that hospitals perform a substantial number of surgical procedures annually. In 2022, around 26.2 million surgical procedures were conducted in the S., indicating a robust demand for anesthesia drugs to facilitate these operations.

The increasing prevalence of chronic diseases such as cardiovascular diseases and cancer drives the need for surgical interventions. The American Cancer Society estimated nearly 2.01 million new cancer cases in the U.S. in 2024, which will necessitate more surgeries and subsequently increase the demand for anesthesia

Continuous innovations in drug formulations and delivery methods enhance patient safety and efficacy. The general Anesthesia Drugs Market is projected to grow at a CAGR of 3% from 2024 to 2033, driven by advancements that improve recovery times and reduce complications associated with anesthesia.

Anesthesia Drugs Market Segmentation Analysis

Anesthesia Drugs Market, By Application

General Surgery
Orthopedic Surgery
Ophthalmology
Dentistry
Pain Treatment

Based on Application, the market is segmented into energy General Surgery, Orthopedic Surgery, Ophthalmology, Dentistry, and Pain Treatment. The general surgery segment captured a substantial revenue share of 46.8% in 2023. This dominance is attributed to the extensive use of anesthesia drugs during a wide range of surgical procedures, making it the largest application area in the market.

Anesthesia Drugs Market, By Administrative Route

Inhalational
Intravenous (IV)
Topical
Local Infiltration

Based on Administrative Route, the market is segmented into Inhalational, Intravenous (IV), Topical, and Local Infiltration. The intravenous drug segment captured a remarkable market revenue share of 56.4% in 2023. This dominance is attributed to the efficiency and reliability of IV administration, which allows for precise dose delivery and rapid onset of anesthesia during surgical procedures.

Anesthesia Drugs Market, By Mode of Delivery

Pre-filled Syringes and Vials
Ampoules
Metered-dose inhalers (MDIs)

Based on Mode of Delivery, the market is divided into Pre-filled Syringes and Vials, Ampoules, and Metered-Dose Inhalers (MDIs). Pre-filled syringes and vials account for a significant share of the Anesthesia Drugs Market due to their convenience and efficiency. They are favored for their ability to provide accurate dosing and reduce preparation time, making them particularly useful in emergency situations.

Key Players

The "Anesthesia Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the Abbott Laboratories, AbbVie, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Aspen Pharmacare Holdings Limited, Baxter International, Inc., Boehringer Ingelheim International GmbH, Claris Lifesciences Limited, Maruishi Pharmaceutical Co. Ltd., Mylan NV, Pacira Pharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above- mentioned players globally.

Anesthesia Drugs Market Recent Developments
In February 2024, Hikma Pharmaceuticals launched Fentanyl Citrate Injection, USP, designed for short-duration analgesia during maintenance, induction, premedication, anesthesia, and immediate postoperative recovery. This product addresses a critical need for effective pain management in various surgical settings.
In June 2023, AstraZeneca entered into a strategic partnership with Aspen Global Incorporated (AGI) to expand the commercialization of its anesthesia medicines portfolio outside the U.S. This agreement covers several established anesthetic products, enhancing their availability in global markets and leveraging AGI's extensive commercial network.

1. INTRODUCTION OF GLOBAL ANESTHESIA DRUGS MARKET

1.1. Overview of the market
1.2. Scope of the report
1.3. Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ANESTHESIA DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5. GLOBAL ANESTHESIA DRUGS MARKET, BY APPLICATION

5.1 Overview
5.2 General Surgery
5.3 Orthopedic Surgery
5.4 Ophthalmology
5.5 Dentistry
5.6 Pain Treatment

6. GLOBAL ANESTHESIA DRUGS MARKET, BY ADMINISTRATIVE ROUTE

6.1 Overview
6.2 Inhalational
6.3 Intravenous (IV)
6.4 Topical
6.5 Local Infiltration

7. GLOBAL ANESTHESIA DRUGS MARKET, BY MODE OF DELIVERY

7.1 Overview
7.2 Pre-filled Syringes and Vials
7.3 Ampoules
7.4 Metered-dose inhalers (MDIs)

8 GLOBAL ANESTHESIA DRUGS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9. GLOBAL ANESTHESIA DRUGS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company market ranking
9.3 Key development strategies

10. Company profiles

10.1 Abbott Laboratories
- 10.1.1 Overview
- 10.1.2 Financial performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 AbbVie, Inc.
- 10.2.1 Overview
- 10.2.2 Financial performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 AstraZeneca PLC
- 10.3.1 Overview
- 10.3.2 Financial performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 F. Hoffmann-La Roche Ltd.
- 10.4.1 Overview
- 10.4.2 Financial performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Pfizer, Inc.
- 10.5.1 Overview
- 10.5.2 Financial performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Aspen Pharmacare Holdings Limited
- 10.6.1 Overview
- 10.6.2 Financial performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Baxter International, Inc.
- 10.7.1 Overview
- 10.7.2 Financial performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Boehringer Ingelheim International GmbH
- 10.8.1 Overview
- 10.8.2 Financial performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Claris Lifesciences Limited
- 10.9.1 Overview
- 10.9.2 Financial performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Maruishi Pharmaceutical Co. Ltd.
- 10.10.1 Overview
- 10.10.2 Financial performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 Mylan NV
- 10.11.1 Overview
- 10.11.2 Financial performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Pacira Pharmaceuticals, Inc
- 10.12.1 Overview
- 10.12.2 Financial performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments